SMMT logo

SMMT
Summit Therapeutics Inc

9,578
Mkt Cap
$11.87B
Volume
2.45M
52W High
$36.91
52W Low
$13.83
PE Ratio
-12.84
SMMT Fundamentals
Price
$15.94
Prev Close
$15.87
Open
$15.68
50D MA
$16.69
Beta
1.63
Avg. Volume
3.2M
EPS (Annual)
-$0.308
P/B
61.72
Rev/Employee
$0.00
$12,416.92
Loading...
Loading...
News
all
press releases
Skandinaviska Enskilda Banken AB publ Has $6.99 Million Holdings in Summit Therapeutics PLC $SMMT
Skandinaviska Enskilda Banken AB publ grew its position in Summit Therapeutics PLC (NASDAQ:SMMT - Free Report) by 409.2% in the 3rd quarter, according to the company in its most recent Form 13F...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026
Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) will host an earnings call to announce its fourth quarter and full year 2025 financial results and provide an operational update...
Business Wire·5d ago
News Placeholder
Summit Therapeutics (SMMT) to Release Earnings on Monday
Summit Therapeutics (NASDAQ:SMMT) will be releasing its Q4 2025 earnings before the market opens on Monday, February 23. (View Earnings Report at...
MarketBeat·7d ago
News Placeholder
MRK Up More Than 7% on Improved Long-Term Prospects: Still a Sell?
Merck stock has risen more than 7% in a month on a stronger long-term outlook, but 2026 headwinds, Keytruda patent risk and Gardasil slump keep it a Sell.
Zacks·10d ago
News Placeholder
EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) DelveInsight
EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast...
PR Newswire·11d ago
News Placeholder
Summit Therapeutics PLC (NASDAQ:SMMT) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Summit Therapeutics PLC (NASDAQ:SMMT - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the seventeen ratings firms that are covering the company, MarketBeat.com...
MarketBeat·14d ago
News Placeholder
Summit Therapeutics (NASDAQ:SMMT) Rating Lowered to Strong Sell at Zacks Research
Zacks Research lowered shares of Summit Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Wednesday...
MarketBeat·17d ago
News Placeholder
Summit Therapeutics (NASDAQ:SMMT) Reaches New 12-Month Low - Should You Sell?
Summit Therapeutics (NASDAQ:SMMT) Reaches New 52-Week Low - Here's Why...
MarketBeat·20d ago
News Placeholder
2 Stocks That Could Soar This Year
Key PointsExelixis and Summit Therapeutics could have significant catalysts this year...
Nasdaq News: Markets·22d ago
News Placeholder
Yong Rong HK Asset Management Ltd Invests $2.07 Million in Summit Therapeutics PLC $SMMT
Yong Rong HK Asset Management Ltd bought a new stake in Summit Therapeutics PLC (NASDAQ:SMMT - Free Report) in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm bought...
MarketBeat·23d ago
<
1
2
...
>

Latest SMMT News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.